{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:45:24Z","timestamp":1790999124089,"version":"4.1.0"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,11,12]],"date-time":"2015-11-12T00:00:00Z","timestamp":1447286400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007123","name":"Stanley Medical Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007123","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Union FP7","award":["223427"],"award-info":[{"award-number":["223427"]}]},{"name":"European Union FP7","award":["286334"],"award-info":[{"award-number":["286334"]}]},{"DOI":"10.13039\/501100015066","name":"Virgo consortium","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100015066","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Netherlands Genomics Initiative"},{"name":"Dutch Fund for Economic Structure Reinforcement"},{"name":"NeuroBasic PharmaPhenomics project"},{"DOI":"10.13039\/501100000266","name":"Engineering and Physical Sciences Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000266","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain, Behavior, and Immunity"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.bbi.2015.10.019","type":"journal-article","created":{"date-parts":[[2015,11,4]],"date-time":"2015-11-04T10:00:26Z","timestamp":1446631226000},"page":"178-186","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients"],"prefix":"10.1016","volume":"52","author":[{"given":"Jakub","family":"Tomasik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago G.","family":"Lago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Rothermundt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. Markus","family":"Leweke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nico J.M.","family":"van Beveren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C.","family":"Guest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Rahmoune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Bahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbi.2015.10.019_b0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.schres.2006.11.016","article-title":"Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial","volume":"90","author":"Akhondzadeh","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2015.10.019_b0010","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/S0188-4409(02)00403-4","article-title":"Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol","volume":"33","author":"Atmaca","year":"2002","journal-title":"Arch. Med. Res."},{"key":"10.1016\/j.bbi.2015.10.019_b0015","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s002329900111","article-title":"Reversible binding of long-chain fatty acids to purified FAT, the adipose CD36 homolog","volume":"153","author":"Baillie","year":"1996","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.bbi.2015.10.019_b0020","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.02.011","article-title":"Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia","volume":"93","author":"Bartzokis","year":"2007","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2015.10.019_b0025","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.tem.2006.02.005","article-title":"Focus on prolactin as a metabolic hormone","volume":"17","author":"Ben-Jonathan","year":"2006","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.bbi.2015.10.019_b0030","first-page":"639","article-title":"Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects","volume":"17","author":"Ben-Jonathan","year":"1996","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.bbi.2015.10.019_b0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. B"},{"key":"10.1016\/j.bbi.2015.10.019_b0040","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0006-3223(01)01324-5","article-title":"Association between promoter polymorphic haplotypes of interleukin-10 gene and schizophrenia","volume":"51","author":"Bocchio Chiavetto","year":"2002","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0045","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/978-3-7091-6721-2_20","article-title":"Heart type fatty acid binding protein (H-FABP) is decreased in brains of patients with Down syndrome and Alzheimer\u2019s disease","author":"Cheon","year":"2003","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.bbi.2015.10.019_b0050","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1471-244X-9-57","article-title":"Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects","volume":"9","author":"Choi","year":"2009","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0055","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.schres.2008.07.006","article-title":"Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study","volume":"105","author":"Daumit","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2015.10.019_b0060","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2125.2001.01308.x","article-title":"Biomarkers for the effects of antipsychotic drugs in healthy volunteers","volume":"51","author":"de Visser","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bbi.2015.10.019_b0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.schres.2014.02.005","article-title":"Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment","volume":"154","author":"de Witte","year":"2014","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2015.10.019_b0070","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1176\/appi.ajp.159.1.103","article-title":"Antipsychotic medication adherence: is there a difference between typical and atypical agents?","volume":"159","author":"Dolder","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0075","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/09537109609023591","article-title":"Arachidonic acid uptake by human platelets is mediated by CD36","volume":"7","author":"Dutta-Roy","year":"1996","journal-title":"Platelets"},{"key":"10.1016\/j.bbi.2015.10.019_b0080","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1093\/schbul\/23.4.637","article-title":"Determinants of medication compliance in schizophrenia: empirical and clinical findings","volume":"23","author":"Fenton","year":"1997","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2015.10.019_b0085","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrd2589","article-title":"Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets","volume":"7","author":"Furuhashi","year":"2008","journal-title":"Nat. Rev. Drug Discovery"},{"key":"10.1016\/j.bbi.2015.10.019_b0090","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.hlc.2010.06.665","article-title":"Heart fatty acid binding protein (H-FABP) as a diagnostic biomarker in patients with acute coronary syndrome","volume":"19","author":"Gururajan","year":"2010","journal-title":"Heart Lung Circ."},{"key":"10.1016\/j.bbi.2015.10.019_b0095","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1172\/JCI0214596","article-title":"Defective fatty acid uptake modulates insulin responsiveness and metabolic responses to diet in CD36-null mice","volume":"109","author":"Hajri","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbi.2015.10.019_b0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1023\/A:1020502624234","article-title":"Insights into binding of fatty acids by fatty acid binding proteins","volume":"239","author":"Hanhoff","year":"2002","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.bbi.2015.10.019_b0105","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2009.11.007","article-title":"Antidiabetic effects of IGFBP2, a leptin-regulated gene","volume":"11","author":"Hedbacker","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.bbi.2015.10.019_b0110","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.mp.4002000","article-title":"Metabolomic mapping of atypical antipsychotic effects in schizophrenia","volume":"12","author":"Kaddurah-Daouk","year":"2007","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0115","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","article-title":"Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia","volume":"157","author":"Kapur","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0120","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/01.pra.0000358319.81307.a5","article-title":"Effects of olanzapine and risperidone on metabolic factors in children and adolescents: a retrospective evaluation","volume":"15","author":"Khan","year":"2009","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.bbi.2015.10.019_b0125","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","article-title":"From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase","volume":"104","author":"Kim","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.bbi.2015.10.019_b0130","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.psyneuen.2008.08.016","article-title":"Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever","volume":"34","author":"Kluge","year":"2009","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.bbi.2015.10.019_b0135","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","article-title":"H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs","volume":"28","author":"Kroeze","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2015.10.019_b0140","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0145","doi-asserted-by":"crossref","first-page":"520","DOI":"10.4088\/JCP.09m05117yel","article-title":"Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial","volume":"71","author":"Laan","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.bbi.2015.10.019_b0150","first-page":"S163","article-title":"Fatty acids and schizophrenia","volume":"31","author":"Laugharne","year":"1996","journal-title":"Lipids"},{"issue":"Suppl 1","key":"10.1016\/j.bbi.2015.10.019_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4088\/JCP.13049su1c.02","article-title":"Measurements of response, remission, and recovery in schizophrenia and examples for their clinical application","volume":"75","author":"Leucht","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0160","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","author":"Leucht","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bbi.2015.10.019_b0165","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1038\/sj.npp.1301325","article-title":"Defining \u2019response\u2019 in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs","volume":"32","author":"Leucht","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.bbi.2015.10.019_b0170","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1387\/ijdb.092976rl","article-title":"Fatty acid binding proteins in brain development and disease","volume":"54","author":"Liu","year":"2010","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.bbi.2015.10.019_b0175","series-title":"Randomization, Bootstrap, and Monte Carlo Methods in Biology","author":"Manly","year":"2007"},{"key":"10.1016\/j.bbi.2015.10.019_b0180","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/schbul\/2.1.19","article-title":"The dopamine hypothesis of schizophrenia: a review","volume":"2","author":"Meltzer","year":"1976","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.bbi.2015.10.019_b0185","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3389\/fphys.2012.00385","article-title":"The multiple roles of fatty acid handling proteins in brain","volume":"3","author":"Moulle","year":"2012","journal-title":"Front. Physiol."},{"key":"10.1016\/j.bbi.2015.10.019_b0190","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.schres.2010.04.015","article-title":"Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment","volume":"121","author":"Muller","year":"2010","journal-title":"Schizophr. Res."},{"issue":"Suppl 1","key":"10.1016\/j.bbi.2015.10.019_b0195","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNS Drugs"},{"issue":"Suppl 4","key":"10.1016\/j.bbi.2015.10.019_b0200","first-page":"8","article-title":"Antipsychotic medications: metabolic and cardiovascular risk","volume":"68","author":"Newcomer","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0205","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1253\/circj.71.1452","article-title":"Circulating levels of heart-type fatty acid-binding protein in a general Japanese population: effects of age, gender, and physiologic characteristics","volume":"71","author":"Niizeki","year":"2007","journal-title":"Circ. J."},{"key":"10.1016\/j.bbi.2015.10.019_b0210","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/15622970802626580","article-title":"Interleukin-10 gene promoter polymorphism in patients with schizophrenia in a region of East Turkey","volume":"10","author":"Ozbey","year":"2009","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0215","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/353164a0","article-title":"Dopamine activation of the arachidonic acid cascade as a basis for D1\/D2 receptor synergism","volume":"353","author":"Piomelli","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.bbi.2015.10.019_b0220","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00213-005-2231-5","article-title":"5-HT2A\/2C receptor signaling via phospholipase A2 and arachidonic acid is attenuated in mice lacking the serotonin reuptake transporter","volume":"180","author":"Qu","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.bbi.2015.10.019_b0225","unstructured":"R Core Team, 2014. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria. <http:\/\/www.R-project.org\/>."},{"key":"10.1016\/j.bbi.2015.10.019_b0230","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archpsyc.56.3.241","article-title":"Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder","volume":"56","author":"Robinson","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0235","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S1474-4422(09)70016-X","article-title":"Matrix metalloproteinases and their multiple roles in neurodegenerative diseases","volume":"8","author":"Rosenberg","year":"2009","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bbi.2015.10.019_b0240","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/01.STR.32.5.1162","article-title":"White matter damage is associated with matrix metalloproteinases in vascular dementia","volume":"32","author":"Rosenberg","year":"2001","journal-title":"Stroke"},{"key":"10.1016\/j.bbi.2015.10.019_b0245","doi-asserted-by":"crossref","first-page":"e82","DOI":"10.1038\/tp.2012.3","article-title":"Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients","volume":"2","author":"Schwarz","year":"2012","journal-title":"Transl Psychiatry"},{"key":"10.1016\/j.bbi.2015.10.019_b0250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.4137\/BMI.S4877","article-title":"Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia","volume":"5","author":"Schwarz","year":"2010","journal-title":"Biomark Insights"},{"key":"10.1016\/j.bbi.2015.10.019_b0255","doi-asserted-by":"crossref","first-page":"18957","DOI":"10.1074\/jbc.M113.527341","article-title":"FABP3 protein promotes alpha-synuclein oligomerization associated with 1-methyl-1,2,3,6-tetrahydropiridine-induced neurotoxicity","volume":"289","author":"Shioda","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bbi.2015.10.019_b0260","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1523\/JNEUROSCI.4140-09.2010","article-title":"Heart-type fatty acid binding protein regulates dopamine D2 receptor function in mouse brain","volume":"30","author":"Shioda","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.bbi.2015.10.019_b0265","first-page":"872","article-title":"Association and coexpression of fatty-acid-binding protein and glycoprotein CD36 in the bovine mammary gland","volume":"230","author":"Spitsberg","year":"1995","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bbi.2015.10.019_b0270","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.schres.2007.11.033","article-title":"World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia","volume":"100","author":"Tandon","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.bbi.2015.10.019_b0275","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1385\/MN:34:2:109","article-title":"Molecular profiling of antipsychotic drug function: convergent mechanisms in the pathology and treatment of psychiatric disorders","volume":"34","author":"Thomas","year":"2006","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bbi.2015.10.019_b0280","unstructured":"World Health Organization, 2014. What is schizophrenia? <http:\/\/www.who.int\/mental_health\/management\/schizophrenia\/en\/> (accessed 18 Sep 2014)."},{"key":"10.1016\/j.bbi.2015.10.019_b0285","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.schres.2014.03.024","article-title":"Decreased interleukin-10 serum levels in first-episode drug-naive schizophrenia: relationship to psychopathology","volume":"156","author":"Xiu","year":"2014","journal-title":"Schizophr. Res."}],"container-title":["Brain, Behavior, and Immunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159115300453?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889159115300453?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:41:06Z","timestamp":1760168466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889159115300453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":57,"alternative-id":["S0889159115300453"],"URL":"https:\/\/doi.org\/10.1016\/j.bbi.2015.10.019","relation":{},"ISSN":["0889-1591"],"issn-type":[{"value":"0889-1591","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretreatment levels of the fatty acid handling proteins H-FABP and CD36 predict response to olanzapine in recent-onset schizophrenia patients","name":"articletitle","label":"Article Title"},{"value":"Brain, Behavior, and Immunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbi.2015.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}